LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 122

Suchoptionen

  1. Artikel ; Online: DARTs point the way forward in AML.

    Gill, Saar

    Blood

    2021  Band 137, Heft 6, Seite(n) 720–721

    Mesh-Begriff(e) Antibodies, Bispecific ; Humans ; Immunologic Factors ; Immunotherapy ; Leukemia, Myeloid, Acute
    Chemische Substanzen Antibodies, Bispecific ; Immunologic Factors
    Sprache Englisch
    Erscheinungsdatum 2021-02-10
    Erscheinungsland United States
    Dokumenttyp Editorial ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2020009020
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Hypoimmune cells resist rejection in monkeys.

    Borrero Borrego, Asuncion / Gill, Saar

    Nature biotechnology

    2023  Band 42, Heft 3, Seite(n) 380–382

    Mesh-Begriff(e) Animals ; Transplantation, Homologous ; Macaca fascicularis ; Graft Rejection
    Sprache Englisch
    Erscheinungsdatum 2023-10-21
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1311932-1
    ISSN 1546-1696 ; 1087-0156
    ISSN (online) 1546-1696
    ISSN 1087-0156
    DOI 10.1038/s41587-023-02013-1
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Good CARMA: Turning bad tumor-resident myeloid cells good with chimeric antigen receptor macrophages.

    Snyder, Christopher M / Gill, Saar I

    Immunological reviews

    2023  Band 320, Heft 1, Seite(n) 236–249

    Abstract: In religious philosophy, the concept of karma represents the effect of one's past and present actions on one's future. Macrophages are highly plastic cells with myriad roles in health and disease. In the setting of cancer, macrophages are among the most ... ...

    Abstract In religious philosophy, the concept of karma represents the effect of one's past and present actions on one's future. Macrophages are highly plastic cells with myriad roles in health and disease. In the setting of cancer, macrophages are among the most plentiful members of the immune microenvironment where they generally support tumor growth and restrain antitumor immunity. However, macrophages are not necessarily born bad. Macrophages or their immediate progenitors, monocytes, are induced to traffic to the tumor microenvironment (TME) and during this process they are polarized toward a tumor-promoting phenotype. Efforts to deplete or repolarize tumor-associated macrophages (TAM) for therapeutic benefit in cancer have to date disappointed. By contrast, genetic engineering of macrophages followed by their transit into the TME may allow these impressionable cells to mend their ways. In this review, we summarize and discuss recent advances in the genetic engineering of macrophages for the treatment of cancer.
    Mesh-Begriff(e) Humans ; Receptors, Chimeric Antigen/genetics ; Macrophages ; Neoplasms ; Myeloid Cells/pathology ; Monocytes ; Tumor Microenvironment ; Immunotherapy, Adoptive
    Chemische Substanzen Receptors, Chimeric Antigen
    Sprache Englisch
    Erscheinungsdatum 2023-06-09
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 391796-4
    ISSN 1600-065X ; 0105-2896
    ISSN (online) 1600-065X
    ISSN 0105-2896
    DOI 10.1111/imr.13231
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.

    Cummins, Katherine / Gill, Saar

    Hematology/oncology clinics of North America

    2023  Band 37, Heft 6, Seite(n) 1125–1147

    Abstract: Up to 30% of patients with acute myeloid leukemia (AML) who undergo chimeric antigen receptor (CAR) T-cell therapy have evidence of response, although trials are highly heterogeneous. These responses are rarely deep or durable. CD123, CD33, and CLL-1 ... ...

    Abstract Up to 30% of patients with acute myeloid leukemia (AML) who undergo chimeric antigen receptor (CAR) T-cell therapy have evidence of response, although trials are highly heterogeneous. These responses are rarely deep or durable. CD123, CD33, and CLL-1 have emerged as the most common targets for CAR T cells in AML. CAR T cells against myeloid antigens cause myeloablation as well as cytokine release syndrome, although neurotoxicity is rarely seen. Future efforts should focus on AML-specific antigen discovery or engineering, and on further enhancing the activity of CAR T cells.
    Sprache Englisch
    Erscheinungsdatum 2023-07-11
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 93115-9
    ISSN 1558-1977 ; 0889-8588
    ISSN (online) 1558-1977
    ISSN 0889-8588
    DOI 10.1016/j.hoc.2023.06.004
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: CAR T cells engage in anticancer martial arts.

    Gill, Saar

    Science translational medicine

    2018  Band 9, Heft 373

    Abstract: A clever redesign of the chimeric antigen receptor T cell concept turns a cancer-mediated immunosuppressive cytokine into a growth signal. ...

    Abstract A clever redesign of the chimeric antigen receptor T cell concept turns a cancer-mediated immunosuppressive cytokine into a growth signal.
    Mesh-Begriff(e) Humans ; Immunotherapy, Adoptive ; Martial Arts ; Pancreatic Neoplasms ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen ; T-Lymphocytes ; Tumor Microenvironment
    Chemische Substanzen Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen
    Sprache Englisch
    Erscheinungsdatum 2018-02-01
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Comment
    ZDB-ID 2518854-9
    ISSN 1946-6242 ; 1946-6234
    ISSN (online) 1946-6242
    ISSN 1946-6234
    DOI 10.1126/scitranslmed.aal4996
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Epigenetic engineering empowers T cells.

    Tandel, Jayesh V / Gill, Saar I

    Blood

    2022  Band 139, Heft 14, Seite(n) 2091–2092

    Mesh-Begriff(e) Epigenesis, Genetic ; Epigenomics ; T-Lymphocytes
    Sprache Englisch
    Erscheinungsdatum 2022-02-18
    Erscheinungsland United States
    Dokumenttyp Editorial ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2021015016
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: How close are we to CAR T-cell therapy for AML?

    Gill, Saar I

    Best practice & research. Clinical haematology

    2019  Band 32, Heft 4, Seite(n) 101104

    Abstract: Chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has thus far been elusive, in part owing to the absence of truly AML-specific surface antigens, making AML difficult to target. However, progress has been made toward the use ...

    Abstract Chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has thus far been elusive, in part owing to the absence of truly AML-specific surface antigens, making AML difficult to target. However, progress has been made toward the use of CAR T-cell therapy in this disease, prompting the topic of this paper. Discussion and clinical examples of potential solutions to creating a safe and effective CAR T cell for AML include: (1) Decreasing the potency or activity of CAR T cells to enhance the therapeutic window; (2) Using transient or depletable CAR T cells as part of pre-transplant conditioning; and (3) Using a gene-edited allogeneic donor hematopoietic stem cell transplant in order to allow safe and protracted anti-AML CAR T-cell function.
    Mesh-Begriff(e) Allografts ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunotherapy, Adoptive ; Leukemia, Myeloid, Acute/therapy ; Receptors, Chimeric Antigen/therapeutic use ; Transplantation Conditioning
    Chemische Substanzen Receptors, Chimeric Antigen
    Sprache Englisch
    Erscheinungsdatum 2019-10-18
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2048027-1
    ISSN 1532-1924 ; 1521-6926
    ISSN (online) 1532-1924
    ISSN 1521-6926
    DOI 10.1016/j.beha.2019.101104
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Good CARMA: Turning bad tumor‐resident myeloid cells good with chimeric antigen receptor macrophages

    Snyder, Christopher M. / Gill, Saar I.

    Immunological Reviews. 2023 Nov., v. 320, no. 1 p.236-249

    2023  

    Abstract: In religious philosophy, the concept of karma represents the effect of one's past and present actions on one's future. Macrophages are highly plastic cells with myriad roles in health and disease. In the setting of cancer, macrophages are among the most ... ...

    Abstract In religious philosophy, the concept of karma represents the effect of one's past and present actions on one's future. Macrophages are highly plastic cells with myriad roles in health and disease. In the setting of cancer, macrophages are among the most plentiful members of the immune microenvironment where they generally support tumor growth and restrain antitumor immunity. However, macrophages are not necessarily born bad. Macrophages or their immediate progenitors, monocytes, are induced to traffic to the tumor microenvironment (TME) and during this process they are polarized toward a tumor‐promoting phenotype. Efforts to deplete or repolarize tumor‐associated macrophages (TAM) for therapeutic benefit in cancer have to date disappointed. By contrast, genetic engineering of macrophages followed by their transit into the TME may allow these impressionable cells to mend their ways. In this review, we summarize and discuss recent advances in the genetic engineering of macrophages for the treatment of cancer.
    Schlagwörter antigens ; immunity ; macrophages ; monocytes ; neoplasms ; phenotype ; philosophy ; therapeutics
    Sprache Englisch
    Erscheinungsverlauf 2023-11
    Umfang p. 236-249.
    Erscheinungsort John Wiley & Sons, Ltd
    Dokumenttyp Artikel ; Online
    Anmerkung REVIEW
    ZDB-ID 391796-4
    ISSN 1600-065X ; 0105-2896
    ISSN (online) 1600-065X
    ISSN 0105-2896
    DOI 10.1111/imr.13231
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Monkey business: Repurposing a protein from the simian immunodeficiency virus to enhance cytotoxic chemotherapy.

    Gill, Saar

    Science translational medicine

    2017  Band 9, Heft 375

    Abstract: Cytarabine activity in acute myeloid leukemia blasts can be augmented by degrading the expression of a critical hydrolase. ...

    Abstract Cytarabine activity in acute myeloid leukemia blasts can be augmented by degrading the expression of a critical hydrolase.
    Mesh-Begriff(e) Animals ; Cytarabine ; Hematologic Neoplasms ; Leukemia, Myeloid, Acute ; SAM Domain and HD Domain-Containing Protein 1 ; Simian Immunodeficiency Virus
    Chemische Substanzen Cytarabine (04079A1RDZ) ; SAM Domain and HD Domain-Containing Protein 1 (EC 3.1.5.-)
    Sprache Englisch
    Erscheinungsdatum 2017-02-01
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Comment
    ZDB-ID 2518854-9
    ISSN 1946-6242 ; 1946-6234
    ISSN (online) 1946-6242
    ISSN 1946-6234
    DOI 10.1126/scitranslmed.aam6051
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions.

    Gill, Saar / Brudno, Jennifer N

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

    2021  Band 41, Seite(n) 1–20

    Abstract: At the time of writing, five anti-CD19 CAR T-cell products are approved by the U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric B-cell acute lymphoblastic ... ...

    Abstract At the time of writing, five anti-CD19 CAR T-cell products are approved by the U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric B-cell acute lymphoblastic leukemia, and multiple myeloma. CAR T cells for chronic lymphocytic leukemia, acute myeloid leukemia, and less common malignancies such as T-cell lymphomas and Hodgkin lymphoma are being tested in early-phase clinical trials worldwide. The purpose of this overview is to describe the current landscape of CAR T cells in hematologic malignancies, outline their outcomes and toxicities, and explain the outstanding questions that remain to be addressed.
    Mesh-Begriff(e) Antigens, CD19 ; Humans ; Immunotherapy, Adoptive ; Leukemia, Lymphocytic, Chronic, B-Cell/therapy ; Lymphoma, B-Cell/therapy ; Receptors, Antigen, T-Cell
    Chemische Substanzen Antigens, CD19 ; Receptors, Antigen, T-Cell
    Sprache Englisch
    Erscheinungsdatum 2021-05-14
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2431126-1
    ISSN 1548-8756 ; 1548-8748
    ISSN (online) 1548-8756
    ISSN 1548-8748
    DOI 10.1200/EDBK_320085
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang